Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2022

5-year impact of new registered indications on the ESMO-MCBS

Five years of FDA approvals (2017-2022): A report from the ESMO-MCBS

Date

09 Sep 2022

Session

5-year impact of new registered indications on the ESMO-MCBS

Topics

Cytotoxic Therapy;  Targeted Therapy;  Cancer Care Equity Principles and Health Economics;  Immunotherapy

Tumour Site

Presenters

Nathan Cherny

Authors

N.I. Cherny

Author affiliations

  • Oncology Institute, Shaare Zedek Medical Center, 9103102 - Jerusalem/IL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.